Catalent (NYSE:CTLT) said today that it closed its acquisition of Canada-based Accucaps and its pharmaceutical soft-gel manufacturing capabilities. The Somerset, N.J.-based company did not disclose the deal’s financial details. In November last year, Catalent said that it planned to fund the Accucaps buy with a $400 million debt offering. The company also plans to use the private placement […]
Mergers & Acquisitions
Allergan acquires Zeltiq Aesthetics in $2.48B deal
Allergan (NYSE:AGN) said today that it will pay $2.48 billion for Zeltiq Aesthetics Inc. (NSDQ:ZLTQ) and its portfolio of body-contouring products. Zeltiq’s FDA-approved CoolSculpting system uses a cooling mechanism to reduce the appearance of fat which has not responded to diet or exercise, without disturbing surrounding tissue. According to the deal, Allergan agreed to pay […]
How Trelleborg is getting the most out of its acquisitions—including with combo devices
Heather Thompson, Senior Editor As is the case with many medical device industry suppliers, Trelleborg has engaged in a spate of acquisitions to better serve the growing needs of its OEM customers for drug-device combo products and more. Last year, Trelleborg, Sweden–based Trelleborg announced the acquisition of Tustin, California–based Specialty Silicone Fabricators. They’ve made three […]
Allergan closes $3B Acelity LifeCell buy
Acelity said today that it closed the sale of its regenerative medicine unit, LifeCell, to Allergan (NYSE:AGN) for $2.9 billion in cash. The deal brings LifeCell’s regenerative medicine and reconstructive portfolio to Allergan, joining a portfolio of medical aesthetics, breast implant and tissue expander product lines. Dublin-based Allergan said it expects to bring in $450 million in revenue this year, growing […]
Celgene acquires Delinia, beats on Q4 earnings
Shares in Celgene (NSDQ:CELG) fell yesterday, even though the biopharmaceutical company beat earnings expectations on Wall Street with its 4th quarter results. The Summit, N.J.-based company posted profits of $1.29 million, or $1.61 per share, on sales of $2.9 million for the 3 months ended Dec. 31, for bottom-line growth of 34% on sales growth […]
Johnson & Johnson to pay $30B for Actelion
After weeks of exclusive negotiations, Johnson & Johnson (NYSE:JNJ) said on Thursday that it plans to buy Swiss biotech firm Actelion (VTX:ATLN) for $30 billion in an all-cash deal. The companies have reportedly been in talks for months – Sanofi (NYSE:SNY) was also involved in discussions for Actelion, but was sidelined after J&J entered into exclusive negotiations with Actelion last […]
J&J, Actelion still in talks despite Opsumit failure
Although Actelion (VTX:ATLN)’s Opsumit drug candidate missed its primary endpoint in a phase III trial for patients suffering from a deadly heart-lung condition, analysts reportedly concluded that the result is unlikely to have an impact on merger talks with Johnson & Johnson (NYSE:JNJ). The Swiss drugmaker’s trial involved 226 patients with Eisenmenger Syndrome, which causes untreated congenital heart […]
Cytori buys Azaya’s nanoparticle tech in stock deal
Cytori Therapeutics (NSDQ:CYTX) said this week that it bought San Antonio-based Azaya Therapeutics and its nanoparticle cancer drugs in a stock deal. Azaya shareholders will receive $2 million in CTYX stock. San Diego-based Cytori will also pay $2 million upfront for costs associated with Azaya’s new manufacturing facility in San Antonio. Cytori will acquire a […]
Grifols pays $51m for minority stake in Access Biologicals
Grifols (NSDQ:GRFS) said today that it paid $51 million for a 49% stake in Access Biologicals, in a deal that includes an option to acquire the rest of the business. That option, for the remaining 51% share in Vista, Calif.-based Access, goes live in 2022, Grifols said. The agreement also includes a provision to supply Access with non-human-use […]
Mast Therapeutics, Savara ink merger deal
Mast Therapeutics (NYSE:MSTX) and privately-held Savara Inc. said today that the 2 companies have landed a definitive merger agreement, combining their operations. The newly-formed Austin, Texas-based company is expected to be named Savara Inc., and trade on the NYSE market under a new ticker symbol. The combined company will focus on advancing a pipeline of […]
